Practice Areas & Industries: Arnold & Porter LLP

Practice/Industry Group Overview

Arnold & Porter LLP offers a full range of litigation, regulatory, and transactional services to assist clients in the healthcare and healthcare-related industries, including, among others, pharmaceutical, biotech, medical device, and diagnostic companies and healthcare provider organizations. We offer creative, strategic approaches and coordinated, interdisciplinary representation from attorneys across a range of practice areas, including, among others, drug, biologic and medical device production regulation in the US and EU, coverage and reimbursement, fraud and abuse and false claims, contracting and pricing, internal and government investigations, product liability and mass tort litigation, intellectual property, public policy and legislative, antitrust, privacy, and corporate and securities.

Our offices in Washington, DC, London and Brussels allow us to respond to these complex regulatory and compliance challenges in the US and Europe and to coordinate matters for our healthcare clients on a global basis. We assist our clients in routine counseling matters, resolving their issues and concerns and supporting key business operations, and in the most complex crises. Our focus remains on the long-term business and product goals of our clients.

Our recent work for clients in the healthcare industry is varied and extensive. For example, we represented the French pharmaceutical firm Sanofi in its acquisition of Aventis. The merged firm, valued at US$60 billion, is now the third largest pharmaceutical firm in the world. We are currently representing a major pharmaceutical company in responding to civil and criminal investigations involving allegations of off-label promotion. We also played a leading role as national coordinating counsel, trial counsel, and lead settlement counsel for Wyeth in litigation arising from use of the diet drugs Pondimin and Redux. Approximately six million individuals in the US took these products, and their withdrawal from the market led to the filing of class action lawsuits in nearly every state and tens of thousands of individual lawsuits. We are currently handling a high stakes Congressional and agency investigation relating to drug safety and the conduct of a clinical trial.